Pooled results showed that enhanced FOXO3 expression is significantly related to HCC development (OR, 15.98; 95% CI, 1.96–130.02; p = 0.01), finding an elevated heterogeneity (I2 = 60.30%, Q-test p = 0.11) (Figure 2a, Table 3). The gene discussed is FOXO3; the disease is hepatocellular carcinoma.